French biotechnology company Innate Pharma S.A. is making strides in the field of immunotherapy for cancer treatment. Its portfolio includes several products, such as Lacutamab (IPH4102), a KIR3DL2 antibody in Phase II clinical trials for cutaneous T-cell and peripheral T-cell lymphoma, and Monalizumab, an immune checkpoint inhibitor in Phase III clinical trials for advanced solid tumors. The company also has several products in preclinical trials, including IPH43, an anti-MICA/B ADC, and IPH4501, an antibody drug conjugate. Innate Pharma S.A. has partnerships with major pharmaceutical companies like AstraZeneca, Novo Nordisk A/S, and Sanofi, as well as a co-development and license agreement with MedImmune Limited. The company, which was founded in 1999 and is based in Marseille, France, remains committed to developing innovative treatments to improve the lives of cancer patients around the world.
Innate Pharma S.A.'s ticker is IPHA
The company's shares trade on the NASDAQ stock exchange
They are based in Marseille, France
There are 201-500 employees working at Innate Pharma S.A.
It is https://www.innate-pharma.com/
Innate Pharma S.A. is in the Healthcare sector
Innate Pharma S.A. is in the Biotechnology industry
The following five companies are Innate Pharma S.A.'s industry peers: